AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2011
Feb 2, 2011
32125_dirs_2011-02-02_beb98e79-d682-4838-9e17-e6b275fe7144.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2011-02-02
Reporting Person: Wicki Andreas (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 92980 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Stock | $ | Common Stock (1487680) | Indirect | ||
| Common Stock Warrants (Right to Buy) | $2.69 | 2014-01-21 | Common Stock (37192) | Indirect | |
| Common Stock Warrants (Right to Buy) | $13.44 | 2017-12-29 | Common Stock (41841) | Indirect | |
| Convertible Promissory Notes | $ | Common Stock (1021223) | Indirect |
Footnotes
F1: The shares are held by HBM BioVentures (Cayman) Ltd.,("HBM"). The board of directors of HBM (the "HBM Board") has sole voting and investment power with respect to the shares held by such entity and acts by majority vote. The reporting person does not have sole voting or investment power over the securities held by HBM. The reporting person may be deemed to have beneficial ownership of these securities by virtue of his membership on the Board of HBM. The reporting person disclaims beneficial ownership of these securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.
F2: The Series A convertible preferred stock has no expiration date and will automatically convert into Common Stock upon the consummation of the Issuer's initial public offering.
F3: All principal and accrued interest due on these convertible promissory notes will automatically convert into shares of Common Stock upon the consummation of the Issuer's initial public offering at an effective conversion price of approximately $13.44 per share.